The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
Open accessAbstract
BACKGROUND Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and effects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil. METHODS In this randomised, double-blind study, done at 87 sites in 13 countries, we recruited patients with stable, symptomatic chronic heart failure and left ventricular ejection fraction 40% or lower. Patients were randomly assigned equally, via an interactive web response system, to receive 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or placebo for 20 weeks. We assessed the maximum concentration of omecamtiv mecarbil in plasma (primary endpoint) and changes in cardiac function and ventricular diameters. This trial is registered with ClinicalTrials.gov, number NCT01786512. FINDINGS From March 17, 2014, to March 5, 2015, we enrolled 150 patients in the fixed-dose omecamtiv mecarbil group and 149 in the pharmacokinetic-titration and placebo groups. Mean maximum concentration of omecamtiv mecarbil at 12 weeks was 200 (SD 71) ng/mL in the fixed-dose group and 318 (129) ng/mL in the pharmacokinetic-titration group. For the pharmacokinetic-titration group versus placebo group at 20 weeks, least square mean differences were as follows: systolic ejection time 25 ms (95% CI 18-32, p<0·0001), stroke volume 3·6 mL (0·5-6·7, p=0·0217), left ventricular end-systolic diameter -1·8 mm (-2·9 to -0·6, p=0·0027), left ventricular end-diastolic diameter -1·3 mm, (-2·3 to 0·3, p=0·0128), heart rate -3·0 beats per min (-5·1 to -0·8, p=0·0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970 pg/mL (-1672 to -268, p=0·0069). The frequency of adverse clinical events did not differ between groups. INTERPRETATION Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter. FUNDING Amgen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Third Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., Thygesen, K., Alpert, J. S., White, H. D., Jaffe, A. S., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.001 · Cited by 2,621
Systolic Time Intervals in Heart Failure in Man
WEISSLER, A. M., HARRIS, W. S., & SCHOENFELD, C. D. (1968) · Circulation · doi:10.1161/01.cir.37.2.149 · Cited by 1,217
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Malik, F. I., Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., et al. (2011) · Science · doi:10.1126/science.1200113 · Cited by 584
Self-citationKramer, D. G., Trikalinos, T. A., Kent, D. M., Antonopoulos, G. V., Konstam, M. A., & Udelson, J. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.011 · Cited by 492
Exercise-Induced Cardiac Troponin Elevation
Shave, R., Baggish, A., George, K., Wood, M., Scharhag, J., Whyte, G., Gaze, D., & Thompson, P. D. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.037 · Cited by 447
A New Season for Cardiac Troponin Assays: It’s Time to Keep a Scorecard
Apple, F. S. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.128363 · Cited by 438
Risk Prediction in Patients With Heart Failure
Rahimi, K., Bennett, D., Conrad, N., Williams, T. M., Basu, J., Dwight, J., Woodward, M., Patel, A., McMurray, J., & MacMahon, S. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2014.04.008 · Cited by 410
Self-citationMechanisms of Contraction of the Normal and Failing Heart.
(1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-85-3-413_3 · Cited by 366
Solomon, S. D., Foster, E., Bourgoun, M., Shah, A., Viloria, E., Brown, M. W., Hall, W. J., Pfeffer, M. A., & Moss, A. J. (2010) · Circulation · doi:10.1161/circulationaha.110.955039 · Cited by 339
Self-citationCleland, J. G., Teerlink, J. R., Senior, R., Nifontov, E. M., Mc Murray, J. J., Lang, C. C., Tsyrlin, V. A., Greenberg, B. H., Mayet, J., Francis, D. P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61126-4 · Cited by 333
Self-citation
Cited by
Tsutsui, H., Isobe, M., Ito, H., Ito, H., Okumura, K., Ono, M., Kitakaze, M., Kinugawa, K., Kihara, Y., Goto, Y., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0342 · Cited by 704
Metra, M., & Teerlink, J. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31071-1 · Cited by 673
Self-citationCardiac myosin activation with omecamtiv mecarbil in systolic heart failure
Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2025797 · Cited by 656
Self-citationAdvances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies
Yotti, R., Seidman, C. E., & Seidman, J. G. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015306 · Cited by 168
Biering-Sørensen, T., Querejeta Roca, G., Hegde, S. M., Shah, A. M., Claggett, B., Mosley, T. H., Butler, K. R., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.928 · Cited by 76
Self-citation
Metadata
- Authors
- Teerlink, J. R., Felker, G. M., McMurray, J. J. V., Solomon, S. D., Adams, K. F., Cleland, J. G. F., Ezekowitz, J. A., Goudev, A., Macdonald, P., Metra, M., Mitrovic, V., Ponikowski, P., Serpytis, P., Spinar, J., Tomcsányi, J., Vandekerckhove, H. J., Voors, A. A., Monsalvo, M. L., Johnston, J., Malik, F. I., & Honarpour, N.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 388
- Issue
- 10062
- Pages
- 2895-2903
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2558812366
- Cited by
- 290
- References
- 23
- FWCI
- 19.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(16)32049-9
- The paper
- Teerlink, J. R., Felker, G. M., McMurray, J. J. V., Solomon, S. D., Adams, K. F., Cleland, J. G. F., Ezekowitz, J. A., Goudev, A., Macdonald, P., Metra, M., Mitrovic, V., Ponikowski, P., Serpytis, P., Spinar, J., Tomcsányi, J., Vandekerckhove, H. J., Voors, A. A., Monsalvo, M. L., Johnston, J., . . . Honarpour, N. (2016). Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)32049-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.